Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company''s product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.
最新股票文章

為何麥可·貝瑞(Michael Burry)剛剛清倉所有股票
麥可·貝瑞剛剛拋售了超過7,000萬美元的股票,清空了他的整個投資組合,只保留一支股票,並對這家公司加碼,而其他投資人則紛紛出逃。
18:37, 22 7月 2025